Where dopamine meets opioids: A meta-analysis of the placebo effect in restless legs syndrome treatment studies

Brain

Volumn 131, Issue 4, 2008, Pages 902-917

  Fulda, Stephany ^a   Wetter, Thomas C ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Meta analysis; Placebo effect; Restless legs syndrome

Indexed keywords

ANTICONVULSIVE AGENT; BROMOCRIPTINE; CABERGOLINE; CARBAMAZEPINE; CLONAZEPAM; CLONIDINE; DOPAMINE; ENTACAPONE; GABAPENTIN; GABAPENTIN ENACARBIL; HYDROQUININE; LEVODOPA; LISURIDE; OPIATE; OXYCODONE; PERGOLIDE; PLACEBO; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE; SUMANIROLE; UNCLASSIFIED DRUG; VALPROIC ACID;

COCHRANE LIBRARY; CONFIDENCE INTERVAL; DISEASE SEVERITY; HUMAN; INTERNATIONAL RESTLESS LEGS SEVERITY SCALE; LEG MOVEMENT; MEDLINE; MOTOR DYSFUNCTION; POLYSOMNOGRAPHY; PRIORITY JOURNAL; RATING SCALE; RESTLESS LEGS SYNDROME; REVIEW; SLEEP; SLEEP PARAMETERS;

ADULT; DOPAMINE AGONISTS; HUMANS; LEVODOPA; MIDDLE AGED; PLACEBO EFFECT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESTLESS LEGS SYNDROME; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 41849091473     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awm244     Document Type: Review

References (89)

1. Abetz L, Allen R, Follet A, Washburn T, Earley C, Kirsch J, et al. Evaluating the quality of life of patients with restless legs syndrome. Clin Ther 2004; 26: 925-35.
2. Adler CH, Hauser RA, Sethi K, Caviness JN, Marlor L, Anderson WM, et al. Ropinirole for restless legs syndrome: a placebo-controlled crossover trial. Neurology 2004; 62: 1405-7.
3. Agresti A, Coull BA. Approximate is better than "exact" for interval estimation of binomial proportions. Am Stat 1998; 52: 119-26.
4. Allen R, Becker PM, Bogan R, Schmidt M, Kushida CA, Fry JM, et al. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep 2004; 27: 907-14.
5. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisir J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003; 4: 101-19.
6. Amanzio M, Benedetti F. Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. J Neurosci 1999; 19: 484-94.
7. Benedetti F, Arduino C, Amanzio M. Somatotopic activation of opioid systems by target-directed expectations of analgesia. J Neurosci 1999; 19: 3639-48.
8. Benedetti F, Mayberg HS, Wager TD, Stohler CS, Zubieta JK. Neurobiological mechanisms of the placebo effect. J Neurosci 2005; 25: 10390-402.
9. Beneš H, Kurella B, Kummer J, Kazenwadel J, Selzer R, Kohnen R. Rapid onset of action of levodopa in restless legs syndrome: a double-blind, randomized, multicenter, crossover trial. Sleep 1999; 22: 1073-81.
10. Beneš H. TULIR study group. Transdermal lisuride in patients with idiopathic restless legs syndrome: results from a placebo-controlled, double-blind, randomized, multicenter, 12-week dose-finding study. Sleep Med 2005; 6 (Suppl. 2): S156-7.
11. Bogan RK, Fry JM, Schmidt MH, Carson SW, Ritchie SY. Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 2006; 81: 17-27.
12. Boghen D, Lamothe L, Elie R, Godbout R, Montplaisir J. The treatment of the restless legs syndrome with clonazepam: a prospective controlled study. Can J Neurol Sci 1986; 13: 245-7.
13. Colloca L, Benedetti F. Placebo and painkillers: is mind as real as matter? Nat Rev Neurosci 2005; 6: 545-52.
14. de la Fuente-Fernández R, Phillips AG, Zamburlini M, Sossi V, Calne DB, Ruth TJ, et al. Dopamine release in human ventral striatum and expectation of reward. Behav Brain Res 2002; 136: 359-63.
15. de la Fuente-Fernández R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 2001; 293: 1164-6.
16. Einarson TR. Pharmacoeconomic applications of meta-analysis for single groups using antifungal onychomycosis lacquers as an example. Clin Ther 1997; 19: 559-69.
17. Eisensehr I, Ehrenberg BL, Rogge Solti S, Noachtar S. Treatment of idiopathic restless legs syndrome (RLS) with slow-release valproic acid compared with slow-release levodopa/benserazide. J Neurol 2004; 251: 579-83.
18. Fulda S, Wetter TC. Dopamine agonists for the treatment of restless legs syndrome. Expert Opin Pharmacother 2005; 6: 2655-66.
19. Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 2002; 59: 1573-9.
20. Garcia-Borreguero D, Winkelman J, Adams A, Ellis A, Morris M, Lamb J, et al. Efficacy and tolerability of sumanirole in restless legs syndrome: a phase II, randomized, double-blind, placebo-controlled, dose-response study. Sleep Med 2007; 8: 119-27.
21. GlaxoSmithKline. Clinical Trial Register. Study ID: 101468/249. [updated 2005a February 28; cited 2006 October 30]. Available from: http://ctr.gsk.co.uk/ Summary/ropinirole/studylist.asp
22. GlaxoSmithKline. Clinical Trial Register. Study ID: 101468/190. [updated 2005b March 1; cited 2006 October 30]. Available from: http://ctr.gsk.co.uk/ Summary/ropinirole/studylist.asp
23. GlaxoSmithKline. Clinical Trial Register. Study ID: 101468/194. [updated 2005c March 1; cited 2006 October 30]. Available from: http://ctr.gsk.co.uk/ Summary/ropinirole/studylist.asp
24. GlaxoSmithKline. Clinical Trial Register. Study ID: 101468/191. [updated 2005d March 1; cited 2006 October 30]. Available from: http://ctr.gsk.co.uk/ Summary/ropinirole/studylist.asp
25. GlaxoSmithKline. Clinical Trial Register. Study ID: ROP101892. [updated 2006a January 16; cited 2006 October 30]. Available from: http://ctr.gsk.co.uk/ Summary/ropinirole/studylist.asp
26. GlaxoSmithKline. Clinical Trial Register. Study ID: RRL100013. [updated 2006b March 15; cited 2006 October 30]. Available from: http://ctr.gsk.co.uk/ Summary/ropinirole/studylist.asp
27. Goetz CG, Leurgans S, Raman R. Parkinson Study Group. Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease. Mov Disord 2002; 17: 283-8.
28. Hedges LV. Estimation of effect size from a series of independent experiments. Psychol Bull 1982; 92: 490-9.
29. Hening W, Walters AS, Allen RP, Montplaisir J, Myers A, Ferini-Strambi L. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med 2004; 5: 237-46.
30. Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001; 344: 1594-602.
31. Ikemoto S, Panksepp J. The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking. Brain Res Brain Res Rev 1999; 31: 6-41.
32. Inoue Y, Fujita M, Shimizu T, Emura N, Kuroda K, Uchimuram N. Efficacy and safety of pramipexole in Japanese patients with restless legs syndrome. Mov Disord 2006; 21 (Suppl. 15): S442.
33. Kaplan PW, Allen RP, Buchholz DW, Walters JK. A double-blind, placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene. Sleep 1993; 16: 717-23.
34. Kelly M, Mistry P. Tolerability of a forced-dose escalating regimen of ropinirole in patients with RLS. Mov Disord 2005; 20 (Suppl. 10): S63.
35. Kohnen R, Beneš H, Heinrich CR, Kurella B. Development of the disease-specific Restless Legs Syndrome Quality of Life (RLS-QoL) questionnaire. Mov Disord 2002; 17 (Suppl 5): P743.
36. Kohnen R, Beneš H, Leroux M, Stiasny-Kolster K, Oertel WH. Defining clinical relevance of treatment outcome in studies with restless legs syndrome: example from the cabergoline dose-finding trial. Mov Disord 2004; 19 (Suppl. 9): S427-8.
37. Kushida CA, Becker PM, Ellenbogen AL, Walters AS, Canafax DM. XP13512 is well tolerated and effective in treating moderate to serve restless legs syndrome in a 2-week randomized, double-blind, placebo-controlled, exploratory trial. [updated 27 July 2006a; cited 1 March 2007]. Available from: http://www.xenoport.com/assets/pdf/PUB_XP045_Presentation032806.pdf.
38. Kushida CA, Tolson JM. Ropinirole is an effective treatment for patients with restless legs syndrome (RLS) needing extended treatment coverage. Neurology 2006b; 66 (Suppl. 5): A82.
39. Levine JD, Gordon NC, Fields HL. The mechanisms of placebo analgesia. Lancet 1978; 312: 654-7.
40. Lidstone SC, Stoessl AJ. Understanding the placebo effect: contributions from neuroimaging. Mol Imaging Biol 2007; 9: 176-85.
41. Lundvall O, Abom PE, Holm R. Carbamazepine in restless legs. A controlled pilot study. Eur J Clin Pharmacol 1983; 25: 323-4.
42. Lyman GH, Kuderer NM. The strengths and limitations of meta-analyses based on aggregate data. BMC Med Res Methodol 2005; 5: 14.
43. Mahowald MW. Restless leg syndrome and periodic limb movements of sleep. Curr Treat Options Neurol 2003; 5: 251-60.
44. Martin-Soelch C, Leenders KL, Chevalley A-F, Missimer J, Kunig G, Magyar S, et al. Reward mechanisms in the brain and their role in dependence: evidence from neurophysiological and neuroimaging studies. Brain Res Brain Res Rev 2001; 36: 139-49.
45. Masood A, Phillips B. Epidemiology of restless legs syndrome. In: Chokroverty S, Hening WA, Walters AS, editors. Sleep and movement disorders. Philadelphia: Butterworth Heinemann, 2003; p. 316-21.
46. Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S, et al. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry 2000; 48: 830-43.
47. McCall WV, D'Agostino R, Dunn A. A meta-analysis of sleep changes associated with placebo in hypnotic clinical trials. Sleep Med 2003; 4: 57-62.
48. Montagna P, Sassoli de Bianchi L, Zucconi M, Cirignotta F, Lugaresi E. Clonazepam and vibration in restless legs syndrome. Acta Neurol Scand 1984; 69: 428-30.
49. Montplaisir J, Boucher S, Gosselin A, Poirier G, Lavigne G. Persistence of repetitive EEG arousals (K-alpha complexes) in RLS patients treated with L-DOPA. Sleep 1996; 19: 196-9.
50. Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lespérance P. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord 1997; 12: 61-5.
51. Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 1999; 52: 938-43.
52. Morris SB, DeShon RP. Combining effect sizes in meta-analysis with repeated measures and independent-groups designs. Psychol Methods 2002; 7: 105-25.
53. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol 2002; 67: 53-83.
54. Oertel WH, Beneš H, Geisler P, Eisensehr I, Garcia-Borreguero D, Clarenbach P, et al. Rotigotine patch efficacy and safety in the treatment of moderate to severe idiopathic restless legs sydnrome - results from a multi-national double-blind placebo-controlled multi-center dose-finding study. Sleep Med 2005; 6 (Suppl. 2): S159.
55. Oertel WH, Beneš H, Bodenschatz R, Peglau I, Warmuth R, Happe S, et al. Efficacy of cabergoline in restless legs syndrome. A placebo-controlled study with polysomnography (CATOR). Neurology 2006a; 67: 1040-6.
56. Oertel WH, Stiasny-Kolster K, Bergtholdt B, Hallstrom Y, Albo J, Leissner L, et al. Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study. Mov Disord 2006b; 22: 213-9.
57. Partinen M, Hirvonen K, Jama L, Alakuijala A, Hublin C, Tamminen I, et al. Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study - the PRELUDE study. Sleep Med 2006; 7: 407-17.
58. Paulus W, Trenkwalder C. Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome. Lancet Neurol 2006; 5: 878-86.
59. Perlis ML, McCall WV, Jungquist CR, Pigeon WR, Matteson SE. Placebo effects in primary insomnia. Sleep Med Rev 2005; 9: 381-9.
60. Petrovic P, Kalso E, Petersson KM, Ingvar M. Placebo and opioid analgesia - imaging a shared neuronal network. Science 2002; 295: 1737-40.
61. Phillips B, Young T, Finn L, Asher K, Hening WA, Purvis C. Epidemiology of restless legs symptoms in adults. Arch Int Med 2000; 160: 2137-41.
62. Picchietti D, Winkelman JW. Restless legs syndrome, periodic limb movements in sleep, and depression. Sleep 2005; 28: 891-8.
63. Pinheiro JC, Bates DM. Mixed effects models in S and S-PLUS. New York: Springer, 2000.
64. Polo O, Ylä-Sahra R, Hirvonen K, Karvinen J, Vahteristo M, Ellmén J. Levodopa optimized with entacapone decreases periodic limb movements in patients with restless legs syndrome. Mov Disord 2005; 20 (Suppl. 10): S102.
65. Posternak MA, Zimmerman M. Is there a delay in antidepressant effect? A meta-analysis. J Clin Psychiatry 2005; 66: 148-58.
66. R Development Core Team. R: A language and environment for statistical computing. 2005. R Foundation for statistical computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org.
67. Raudenbush SW, Bryk AS. Hierachical linear models. Applications and data analysis. Thousand Oaks: Sage Publications, 2002.
68. Shetty N, Friedman JH, Kieburtz K, Marshall FJ, Oakes D. The placebo response in Parkinson's disease. Parkinson Study Group. Clin Neuropharmacol 1999; 22: 207-12.
69. Stiasny-Kolster K, Beneš H, Peglau I, Hornyak M, Holinka B, Wessel K, et al. Effective cabergoline treatment in idiopathic restless legs syndrome. Neurology 2004a; 63: 2272-9.
70. Stiasny-Kolster K, Kohnen R, Schollmayer E, Móller JC, Oertel WH. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov Disord 2004b; 19: 1432-510.
71. Telstad W, Sorensen O, Larsen S, Lillevold PE, Stensrud P, Nyberg-Hansen R. Treatment of the restless legs syndrome with carbamazepine: a double blind study. Br Med J 1984; 288: 444-6.
72. Thorp ML, Morris CD, Bagby SP. A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. Am J Kidney Dis 2001; 38: 104-8.
73. Trenkwalder C, Garcia-Borreguero D, Montagna P, Lainey E, de Weerd AW, Tidswell P, et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 2004; 75: 92-7.
74. Turner JA, Deyo RA, Loeser JD, Von Korff M, Fordyce WE. The importance of placebo effects in pain treatment and research. JAMA 1994; 271: 1609-14.
75. van Dijk JG, Bollen ELEM, Slootweg J, van der Meer CM, Durian FW, Zwinderman AH. Geen verschil in werkzaamheid tussen hydrokinine en placebo bij het 'restless legs'-syndroom. Ned Tijdschr Geneeskd 1991; 135: 759-63.
76. 11C] diprenorphine PET study. Brain 2005; 128: 906-17.
77. Wager TD, Rilling JK, Smith EE, Sokolik A, Casey KL, Davidson RJ, et al. Placebo-induced changes in fMRI in the anticipation and experience of pain. Science 2004; 303: 1162-7.
78. Wagner ML, Walters AS, Coleman RG, Hening WA, Grasing K, Chokroverty S. Randomized, double-blind, placebo-controlled study of clonidine in restless legs syndrome. Sleep 1996; 19: 52-8.
79. Walach H, Maidhof C. Is the placebo effect dependent on time? A meta-analysis. In: Kirsch I, editor. How expectancies shape experience. Washington DC: American Psychological Association, 1999; p. 321-32.
80. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression. Variable, substantial, and growing. JAMA 2002; 287: 1840-7.
81. Walters AS, Hening WA, Kavey N, Chokroverty S, Gidro-Frank S. A double-blind randomized crossover trial of bromocriptine and placebo in restless legs syndrome. Ann Neurol 1988; 24: 455-8.
82. Walters AS, LeBrocq C, Dhar A, Hening W, Rosen C, Allen RP, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003; 4: 121-32.
83. Walters AS, Ondo WG, Dreykluft T, Grunstein R, Lee D, Sethi K. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord 2004; 19: 1414-23.
84. Walters AS, Wagner ML, Hening WA, Grasing K, Mills R, Chokroverty S, et al. Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep 1993; 16: 327-32.
85. Wetter TC, Eisensehr I, Trenkwalder C. Functional neuroimaging studies in restless legs syndrome. Sleep Med 2004; 5: 401-6.
86. Wetter TC, Stiasny K, Winkelmann J, Buhlinger A, Brandenburg U, Penzel T, et al. A randomized controlled study of pergolide in patients with restless legs syndrome. Neurology 1999; 52: 944-50.
87. Winkelman JW, Sethi KD, Kushida CA, Becker PM, Koester J, Cappola JJ, et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology 2006; 67: 1034-9.
88. Winkelmann J, Wetter TC, Collado-Seidel V, Gasser T, Dichgans M, Yassouridis A, et al. Clinical characteristics and frequency of the hereditary restless legs syndrome in a population of 300 patients. Sleep 2000; 23: 597-602.
89. XenoPort. Data presented at the 20th Annual Meeting of the Associated Professional Sleep Societies (APSS). [updated 27 July 2006; cited 1 March 2007]. Available from: http://www.xenoport.com/assets/pdf/ PUB_APSS_Presentation_June2006.pdf.